November 21, 2026 · Pharmaceuticals
Health Canada's New Risk Management Plan Guidance: What Sponsors Must Do Before 1 April 2027
By Mussarat Fatima

On 19 November 2026, Health Canada issued a new guidance document on submitting risk management plans (RMPs). It is not a routine refresh. It is the operational companion to a change in the law that takes effect on 1 April 2027, when the risk management plan provisions of the Food and Drug Regulations come into force under the Agile Licensing regulations.
From that date, every RMP a sponsor provides to Health Canada must meet the requirements set out in section C.01.701 of the Food and Drug Regulations. RMPs that Health Canada has already accepted become "existing RMPs" and fall under new updating provisions. For pharmaceutical, generic, biologic and radiopharmaceutical sponsors, the message is simple. The window to review your pharmacovigilance documentation against a regulatory standard, rather than an administrative one, is now open, and it closes on 1 April 2027.
What changed on 19 November 2026, and what changes on 1 April 2027
What it is: Health Canada published a consolidated guidance document, Submitting risk management plans. It replaces the 24 February 2025 version and brings earlier notices and the separate opioid targeted RMP guidance into one structured resource. The guidance takes effect on 1 April 2027.
Why it matters: for years, Health Canada requested and reviewed RMPs as a matter of administrative practice, drawing on the International Council for Harmonisation (ICH) E2E guideline. From 1 April 2027, that practice becomes a legal requirement written into the Food and Drug Regulations. A document that was once largely negotiated becomes a regulated deliverable with defined content and defined update obligations.
What to do: treat 1 April 2027 as a firm compliance date. Inventory every RMP you have on file with Health Canada, confirm whether each one has been found acceptable, and map your current pharmacovigilance procedures against the content the regulations will require. Sponsors who wait until a submission is in flight will have far less room to adjust.
The change sits inside a larger modernization. The same Agile Licensing package introduced terms and conditions on drug authorizations, a shift we covered in Health Canada terms and conditions for drugs. The RMP provisions are the pharmacovigilance pillar of that same reform.
What is a risk management plan in Canada
What it is: a risk management plan is a structured document that describes what is known and not known about a drug's safety, the important identified and potential risks, and the activities a sponsor will carry out to characterize, monitor and minimize those risks over the product's life cycle. Health Canada has adopted and integrated the ICH E2E approach to risk management planning.
Why it matters: an RMP is not a one-time filing. It is a living safety commitment. The pharmacovigilance activities and risk minimization measures you describe become expectations Health Canada can hold you to, and the plan must be kept current as the safety profile evolves. When a serious new signal emerges or a new indication is added, the RMP is one of the first documents an inspector or reviewer will ask to see.
What to do: make sure the people who own your RMP understand that it connects to your wider pharmacovigilance system, your periodic safety reporting, your labelling and your commitment tracking. An RMP that is disconnected from day to day pharmacovigilance is a finding waiting to happen.
What section C.01.701 means for your submissions
What it is: section C.01.701 of the Food and Drug Regulations is the provision that will require RMPs to meet defined requirements. Health Canada's notice is explicit: all RMPs provided on or after 1 April 2027 must meet the requirements set out in section C.01.701 of the Food and Drug Regulations.
Why it matters: once a requirement is in the regulations, it is enforceable. A deficiency in an RMP is no longer only a review comment, it can be a regulatory shortfall. Sponsors should expect reviewers to assess RMPs against a consistent, codified standard rather than case by case negotiation.
What to do: build your RMP from the current Health Canada guidance structure, including the Canadian-specific addendum, and confirm that your plan addresses the elements the guidance describes, from safety specification to pharmacovigilance plan to risk minimization measures and their effectiveness. Because the guidance itself notes that it is administrative and that the regulations are the legal instrument, read the Health Canada guidance on submitting risk management plans together with the regulatory text before you finalize a plan.
Who is in scope, and who is not
What it is: the guidance applies to sponsors and market authorization holders of human drugs that fall within the scope of ICH E2E. It sets out clearly which products it covers and which it excludes.
Why it matters: scope decides whether the 1 April 2027 requirement touches your portfolio at all. Natural health product companies, veterinary drug sponsors and most medical device manufacturers are outside this change, while pharmaceutical, biologic and radiopharmaceutical sponsors are squarely inside it.
| Product type | In scope for the RMP provisions? |
|---|---|
| Prescription and non-prescription human drugs, including generic drugs | Yes, within the scope of ICH E2E |
| Biologics as set out in Schedule D (vaccines, fractionated blood products, biotherapeutics including biosimilars) | Yes |
| Radiopharmaceuticals as set out in Schedule C | Yes |
| Natural health products | No |
| Veterinary drugs | No |
| Biocides | No |
| Whole blood and blood components | No |
| Medical devices | No, except when part of a combination product submission in an applicable product category |
If you are unsure how your product is classified, that question usually needs resolving before any RMP work begins. Biosimilar sponsors in particular should note that Schedule D biologics are in scope; we discuss the broader biosimilar evidence expectations in biosimilars in Canada without Phase 3 trials.
Existing RMPs and the transition rules
What it is: an RMP provided before 1 April 2027 will be considered an "existing RMP" if Health Canada has already indicated that it was acceptable, for example through a written notice or an authorization issued without a notice that the RMP was unacceptable. Existing RMPs become subject to the RMP updating provisions once those provisions come into force.
Why it matters: a legacy RMP does not get a permanent pass. The moment the provisions come into force, your accepted RMPs are swept into the updating regime, so a plan written years ago to an older standard may need maintenance to stay compliant as the product evolves.
What to do: know exactly which of your RMPs are "accepted" and will therefore become existing RMPs, and plan for how you will keep them current. The transition also sets rules for submissions that are still in review at the coming-into-force date:
- Division 8 submissions: under section C.08.003.3, an RMP provided before coming into force with a Division 8 pre-market submission, or a supplement, for which no issuance decision has been made, becomes an existing RMP once Health Canada issues the authorization.
- Division 1 submissions: an RMP provided before coming into force with a Division 1 pre-market application, for which a drug identification number (DIN) has not yet been issued, becomes an existing RMP once the DIN is issued.
- RMPs under review at coming into force for pending Division 8 and Division 1 files are expected to meet section C.01.701. Post-market RMPs and updates are expected to meet Health Canada's existing RMP policies as set out in guidance.
Opioid products and targeted RMPs
What it is: the consolidated guidance folds in the former opioid targeted RMP guidance. Prescription opioid-containing products have historically carried additional targeted risk management expectations, and those expectations now live inside the single RMP guidance structure.
Why it matters: opioid sponsors should not treat the consolidation as a relaxation. The targeted measures and follow-up commitments that applied before still apply, and they now sit alongside the general regulatory requirements that take effect on 1 April 2027.
What to do: if you hold authorizations for prescription opioid-containing products, review both the general RMP requirements and the opioid-specific content in the guidance, and confirm your targeted risk minimization measures and follow-up commitments are current and documented.
Compliance checklist: getting ready for 1 April 2027
Use the following checklist to structure your readiness work. It mirrors the kind of gap assessment MFLRC runs for sponsors preparing for a fixed in-force date.
- Build a complete inventory of every RMP on file with Health Canada, with its product, submission type and current status.
- Confirm, for each RMP, whether Health Canada has indicated it is acceptable, so you know which will become existing RMPs.
- Identify any submission that will be in review across 1 April 2027 and confirm its RMP meets section C.01.701.
- Map your current RMP content against the Health Canada guidance structure, including the Canadian-specific addendum.
- Review and update the standard operating procedures that govern RMP preparation, review, approval and updating.
- Confirm your pharmacovigilance system can deliver on the activities and risk minimization measures described in each RMP.
- Establish an RMP updating procedure so existing RMPs stay current under the updating provisions.
- For opioid products, confirm targeted measures and follow-up commitments are documented and current.
- Define clear roles so one owner is accountable for each RMP and its life cycle.
- Build an internal timeline that completes the gap work well before 1 April 2027, not on the deadline.
Common mistakes to avoid
The sponsors who struggle with a fixed in-force date tend to make the same avoidable errors.
- Treating the RMP as a submission formality rather than an ongoing safety commitment that inspectors and reviewers will test against practice.
- Assuming legacy RMPs are grandfathered. Accepted RMPs become existing RMPs and fall under the updating provisions.
- Relying on the guidance alone and not confirming the regulatory text of section C.01.701 and section C.08.003.3.
- Letting the RMP drift from the real pharmacovigilance system, so the plan describes activities the organization does not actually perform.
- Starting readiness work only when a submission is already filed, leaving no time to fix gaps before a review cycle.
- Confusing scope, for example applying the drug RMP requirements to a natural health product, or missing that a combination product can bring a device into scope.
Frequently asked questions
When do Health Canada's new risk management plan requirements take effect?
The RMP provisions of the Food and Drug Regulations come into force on 1 April 2027. The updated guidance document, issued on 19 November 2026, also comes into effect on that date. Until 1 April 2027, RMPs continue to be submitted and reviewed under the interim guidance that took effect on 1 July 2025.
Does the RMP guidance apply to natural health products?
No. The guidance applies to human drugs within the scope of ICH E2E, including prescription and non-prescription drugs, generics, Schedule D biologics and Schedule C radiopharmaceuticals. It does not apply to natural health products, veterinary drugs, biocides, whole blood and blood components, or medical devices, except when a device forms part of a combination product submission.
What is section C.01.701 of the Food and Drug Regulations?
Section C.01.701 is the provision that requires risk management plans to meet defined requirements. Health Canada states that all RMPs provided on or after 1 April 2027 must meet the requirements set out in section C.01.701. The specific content requirements are in the regulations as amended by the Agile Licensing regulations, so confirm the current text on the Justice Laws website before relying on it.
What happens to an RMP that Health Canada already accepted?
An RMP provided before 1 April 2027 that Health Canada has indicated is acceptable becomes an "existing RMP." Existing RMPs become subject to the RMP updating provisions once those provisions come into force, so a plan accepted under an older standard still needs to be maintained.
What happens to a submission that is still under review on 1 April 2027?
For pending Division 8 pre-market submissions, section C.08.003.3 provides that an RMP with no issuance decision at coming into force becomes an existing RMP once an authorization is issued. For pending Division 1 applications, an RMP becomes an existing RMP once the DIN is issued. RMPs under review at coming into force are expected to meet section C.01.701.
Is an RMP required for every drug?
Not automatically. Health Canada may require RMPs where there is significant uncertainty about a drug's risks, or where a serious risk warrants measures beyond labelling. See the Health Canada subpage on when to provide an RMP for examples, and confirm the regulatory triggers that apply from 1 April 2027.
Can we submit an EU-RMP to Health Canada?
Health Canada uses a Canadian-specific addendum alongside the core RMP content. The guidance describes the format of that addendum. Confirm the current preparing and submitting requirements on the Health Canada guidance subpages before assuming any particular foreign RMP format is acceptable without a Canadian addendum.
How MFLRC can help
A fixed in-force date rewards sponsors who prepare early and penalizes those who wait. MF License and Regulatory Consultants (MFLRC) helps pharmaceutical, generic, biologic and radiopharmaceutical sponsors get ready for 1 April 2027 with practical, inspection-ready work rather than generic checklists.
- RMP gap assessments that compare each of your plans against the Health Canada guidance structure and the incoming requirements.
- Canadian-specific addendum drafting and RMP authoring aligned to ICH E2E.
- Pharmacovigilance SOP development and updates, including an RMP updating procedure for existing RMPs.
- Submission support for Division 1 and Division 8 files that will straddle the coming-into-force date.
- Compliance-as-a-Service support so your pharmacovigilance system keeps pace with your RMP commitments.
Does your existing RMP meet section C.01.701? Book an MFLRC RMP readiness assessment and be submission-ready and inspection-ready well before 1 April 2027.
Conclusion
The 19 November 2026 guidance is the clearest signal yet that risk management planning in Canada has moved from administrative practice to regulatory requirement. On 1 April 2027, section C.01.701 applies to every RMP you provide, and your accepted plans become existing RMPs under the updating provisions. Sponsors who inventory their RMPs, confirm their status, and close gaps now will treat the deadline as a formality. Those who wait will meet it under pressure, inside a live submission, with the least room to fix problems.
Sources and references
- Health Canada, Guidance document: Submitting risk management plans (issued 19 November 2026; effective 1 April 2027)
- Health Canada, Notice: New agile regulatory provisions and updated guidance document on submitting risk management plans
- Government of Canada, Food and Drug Regulations (C.R.C., c. 870), as amended by the Agile Licensing regulations
- ICH, E2E Pharmacovigilance Planning guideline
Downloadable Resource
Health Canada RMP Readiness Checklist (1 April 2027)
A one-page checklist to inventory your RMPs, confirm which become existing RMPs, and close gaps against section C.01.701 before the in-force date.
File: MFLRC-RMP-Readiness-Checklist.pdf
Share with others
Tags
